113 related articles for article (PubMed ID: 18454045)
1. Receptor-targeted therapy of human experimental urinary bladder cancers with cytotoxic LH-RH analog AN-152 [AEZS- 108].
Szepeshazi K; Schally AV; Keller G; Block NL; Benten D; Halmos G; Szalontay L; Vidaurre I; Jaszberenyi M; Rick FG
Oncotarget; 2012 Jul; 3(7):686-99. PubMed ID: 22824624
[TBL] [Abstract][Full Text] [Related]
2. Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide.
Dharap SS; Wang Y; Chandna P; Khandare JJ; Qiu B; Gunaseelan S; Sinko PJ; Stein S; Farmanfarmaian A; Minko T
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12962-7. PubMed ID: 16123131
[TBL] [Abstract][Full Text] [Related]
3. In-vivo studies of targeted and localized cancer drug release from microporous poly-di-methyl-siloxane (PDMS) devices for the treatment of triple negative breast cancer.
Eluu SC; Obayemi JD; Salifu AA; Yiporo D; Oko AO; Aina T; Oparah JC; Ezeala CC; Etinosa PO; Ugwu CM; Esimone CO; Soboyejo WO
Sci Rep; 2024 Jan; 14(1):31. PubMed ID: 38167999
[TBL] [Abstract][Full Text] [Related]
4. New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs.
Schally AV; Szepeshazi K; Nagy A; Comaru-Schally AM; Halmos G
Cell Mol Life Sci; 2004 May; 61(9):1042-68. PubMed ID: 15112052
[TBL] [Abstract][Full Text] [Related]
5. CA215 and GnRH receptor as targets for cancer therapy.
Lee G; Cheung AP; Ge B; Zhu M; Giolma B; Li B; Wong E; Li Y; Wang Y; Chen Z; Gu J
Cancer Immunol Immunother; 2012 Oct; 61(10):1805-17. PubMed ID: 22430628
[TBL] [Abstract][Full Text] [Related]
6. Cytotoxic activity and cell specificity of a novel LHRH peptide drug conjugate, D-Cys6-LHRH vedotin, against ovarian cancer cell lines.
Vankadara S; Ke Z; Wang S; Foo SY; Gunaratne J; Lee MA; Koh X; Chia CSB
Chem Biol Drug Des; 2024 Apr; 103(4):e14516. PubMed ID: 38618710
[TBL] [Abstract][Full Text] [Related]
7. LHRH-Targeted Drug Delivery Systems for Cancer Therapy.
Li X; Taratula O; Taratula O; Schumann C; Minko T
Mini Rev Med Chem; 2017; 17(3):258-267. PubMed ID: 27739358
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic dosing and targeting efficacy of Pt-Mal-LHRH towards triple negative breast cancer.
Ndinguri M; Middleton L; Unrine J; Lui S; Rollins J; Nienaber E; Spease C; Williams A; Cormier L
PLoS One; 2023; 18(10):e0287151. PubMed ID: 37816015
[TBL] [Abstract][Full Text] [Related]
9. Adhesion of LHRH/EphA2 to human Triple Negative Breast Cancer tissues.
Ezenwafor TC; Uzonwanne VO; Madukwe JUA; Amin SM; Anye VC; Obayemi JD; Odusanya OS; Soboyejo WO
J Mech Behav Biomed Mater; 2022 Dec; 136():105461. PubMed ID: 36195050
[TBL] [Abstract][Full Text] [Related]
10. A review of the use of somatostatin analogs in oncology.
Keskin O; Yalcin S
Onco Targets Ther; 2013; 6():471-83. PubMed ID: 23667314
[TBL] [Abstract][Full Text] [Related]
11. Radiolabeled peptides and their expanding role in clinical imaging and targeted cancer therapy.
Aloj L; Mansi R; De Luca S; Accardo A; Tesauro D; Morelli G
J Pept Sci; 2024 May; ():e3607. PubMed ID: 38710638
[TBL] [Abstract][Full Text] [Related]
12. WITHDRAWN: The use of nanoparticles in LHRH receptor targeted therapy for cancer.
Norberto SE; Kakar SS
Exp Mol Pathol; 2009 Feb; ():. PubMed ID: 19454264
[TBL] [Abstract][Full Text] [Related]
13. Expression of hypothalamic neurohormones and their receptors in the human eye.
Dubovy SR; Fernandez MP; Echegaray JJ; Block NL; Unoki N; Perez R; Vidaurre I; Lee RK; Nadji M; Schally AV
Oncotarget; 2017 Sep; 8(40):66796-66814. PubMed ID: 28977997
[TBL] [Abstract][Full Text] [Related]
14. Target-specific delivery of siRNA into hepatoma cells' cytoplasm by bifunctional carrier peptide.
Liu X; Zhu L; Ma J; Qiao X; Zhu D; Liu L; Leng X
Drug Deliv Transl Res; 2017 Feb; 7(1):147-155. PubMed ID: 27896668
[TBL] [Abstract][Full Text] [Related]
15. TAT-LHRH conjugated low molecular weight chitosan as a gene carrier specific for hepatocellular carcinoma cells.
Liu L; Dong X; Zhu D; Song L; Zhang H; Leng XG
Int J Nanomedicine; 2014; 9():2879-89. PubMed ID: 24959076
[TBL] [Abstract][Full Text] [Related]
16. Growth inhibition of tumor cells in vitro by using monoclonal antibodies against gonadotropin-releasing hormone receptor.
Lee G; Ge B
Cancer Immunol Immunother; 2010 Jul; 59(7):1011-9. PubMed ID: 20182875
[TBL] [Abstract][Full Text] [Related]
17. Therapy of experimental hepatic cancers with cytotoxic peptide analogs targeted to receptors for luteinizing hormone-releasing hormone, somatostatin or bombesin.
Szepeshazi K; Schally AV; Treszl A; Seitz S; Halmos G
Anticancer Drugs; 2008 Apr; 19(4):349-58. PubMed ID: 18454045
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of therapeutic effects of targeted cytotoxic analogs of somatostatin and bombesin on human gastric carcinomas.
Szepeshazi K; Schally AV; Nagy A; Wagner BW; Bajo AM; Halmos G
Cancer; 2003 Oct; 98(7):1401-10. PubMed ID: 14508826
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207.
Stangelberger A; Schally AV; Nagy A; Szepeshazi K; Kanashiro CA; Halmos G
Prostate; 2006 Feb; 66(2):200-10. PubMed ID: 16173040
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
